SCHEMBL852465

SCHEMBL852465

OB(O)c1ccc(OC2CCCCO2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 3/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
ENPP2 Q13822 2/20 0.39
HSD11B1 P28845 1/20 0.38
DHFR P00374 1/20 0.36
KDM4C Q9H3R0 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
NPY4R P50391 1/20 0.33
NPY5R Q15761 1/20 0.33
ACP1 P24666 1/20 0.32
MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951257 0.87 CA1 (0.40) TNK2MEN1KMT2ACA1CA2
SCHEMBL3500438 0.86 TNK2 (0.44) TNK2MEN1KMT2AHSD11B1DHFR
SCHEMBL2938910 0.84 MEN1 (0.40) TNK2MEN1KMT2AHSD11B1DHFR
SCHEMBL29950815 0.82 DHFR (0.46) TNK2MEN1KMT2AENPP2HSD11B1
SCHEMBL222919 0.81 MEN1 (0.43) TNK2MEN1KMT2ACA1CA2
SCHEMBL15093765 0.81 MEN1 (0.43) TNK2MEN1KMT2ACA1CA2
SCHEMBL15093959 0.81 MEN1 (0.43) TNK2MEN1KMT2ACA1CA2
SCHEMBL15376865 0.81 TNK2 (0.36) TNK2MEN1KMT2AHSD11B1DHFR
SCHEMBL15869184 0.80 TNK2 (0.40) TNK2MEN1KMT2AHSD11B1DHFR
SCHEMBL7363974 0.80 MEN1 (0.58) MEN1KMT2ACA1CA2ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119463098-A Polyurethane prepolymer and composition based on supermolecule weaving crosslinking and preparation method thereof 浙江大学杭州国际科创中心 2025-02-18 CN claimed
US-12619147-B2 Actinic ray-sensitive or radiation-sensitive resin composition, actinic ray-sensitive or radiation-sensitive film, pattern forming method, and method for manufacturing electronic device FUJIFILM CORPORATION (JP) 2026-05-05 US disclosed
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 US disclosed
US-12612371-B2 Sigma-1 receptor ligands and therapeutic uses thereof UNIVERSITE DE STRASBOURG (FR) 2026-04-28 US disclosed
CN-114450631-B Actinic-ray-or radiation-sensitive resin composition, actinic-ray-or radiation-sensitive film, pattern forming method, and method for manufacturing electronic device 富士胶片株式会社 2025-06-03 CN disclosed
CN-113493694-B Compound, liquid crystal composition and liquid crystal display element 石家庄诚志永华显示材料有限公司 2025-03-11 CN disclosed
CN-119569549-A 2-Phenyl naphthalene derivative and application thereof in preparation of anti-liver cancer drugs 浙江大学 2025-03-07 CN disclosed
US-12234402-B2 Mesogen compounds TRANSITIONS OPTICAL, LTD. (IE) 2025-02-25 US disclosed
CN-119463098-A Polyurethane prepolymer and composition based on supermolecule weaving crosslinking and preparation method thereof 浙江大学杭州国际科创中心 2025-02-18 CN disclosed
CN-113166649-B Mesogenic compounds 光学转变有限公司 2024-05-28 CN disclosed
WO-2005095544-A1 LIQUID CRYSTAL COMPOUNDS, LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2005-10-13 WO disclosed
EP-1501514-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-02-02 EP disclosed
WO-2003093297-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2003-11-13 WO disclosed
EP-0832082-B1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ASTRAZENECA AB (SE) 2001-11-21 EP disclosed
US-6258817-B1 PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS ZENECA LTD. (GB) 2001-07-10 US disclosed
US-6060475-A Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof ZENECA LIMITED (GB) 2000-05-09 US disclosed
US-5866568-A ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY ZENECA LIMITED (GB) 1999-02-02 US disclosed
EP-0832082-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1998-04-01 EP disclosed
US-5668137-A N-heterocyclic sulfonamides having endothelin receptor activity ZENECA LTD. (GB) 1997-09-16 US disclosed
WO-1996040681-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612371-B2 Sigma-1 receptor ligands and therapeutic uses thereof SIGMAR1, OPRL1, OPRM1 TNK2 3198/4885MEN1 4568/4885KMT2A 3285/4885
US-12619147-B2 Actinic ray-sensitive or radiation-sensitive resin composition, actinic ray-sensitive or radiation-sensitive film, pattern forming method, and method for manufacturing electronic device RAD51, COL1A1, CROCC TNK2 1156/4885MEN1 380/4885KMT2A 4005/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 TNK2 1577/4885MEN1 3186/4885KMT2A 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.